Two Sigma Investments LP grew its stake in Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) by 276.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 64,413 shares of the biopharmaceutical company’s stock after purchasing an additional 47,313 shares during the period. Two Sigma Investments LP owned approximately 0.12% of Tetraphase Pharmaceuticals worth $406,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of TTPH. JPMorgan Chase & Co. bought a new stake in shares of Tetraphase Pharmaceuticals in the 3rd quarter valued at approximately $7,915,000. BlackRock Inc. lifted its stake in shares of Tetraphase Pharmaceuticals by 21.2% during the 4th quarter. BlackRock Inc. now owns 4,044,340 shares of the biopharmaceutical company’s stock worth $25,479,000 after acquiring an additional 707,296 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Tetraphase Pharmaceuticals by 32.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,461,807 shares of the biopharmaceutical company’s stock worth $9,998,000 after acquiring an additional 360,552 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Tetraphase Pharmaceuticals by 77.6% during the 4th quarter. Renaissance Technologies LLC now owns 592,493 shares of the biopharmaceutical company’s stock worth $3,733,000 after acquiring an additional 258,908 shares during the last quarter. Finally, Deutsche Bank AG lifted its stake in shares of Tetraphase Pharmaceuticals by 168.6% during the 4th quarter. Deutsche Bank AG now owns 221,425 shares of the biopharmaceutical company’s stock worth $1,394,000 after acquiring an additional 138,996 shares during the last quarter. 58.50% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ TTPH opened at $3.24 on Tuesday. The firm has a market cap of $164.07, a price-to-earnings ratio of -1.23 and a beta of 2.61. Tetraphase Pharmaceuticals Inc. has a twelve month low of $2.05 and a twelve month high of $8.75.
TTPH has been the subject of a number of research analyst reports. SunTrust Banks reissued a “buy” rating and set a $10.00 price target on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, February 14th. Stifel Nicolaus decreased their price target on Tetraphase Pharmaceuticals from $13.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, February 14th. HC Wainwright decreased their price target on Tetraphase Pharmaceuticals from $17.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, February 14th. B. Riley initiated coverage on Tetraphase Pharmaceuticals in a research note on Monday, February 12th. They set a “buy” rating and a $11.00 price target for the company. Finally, Gabelli raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 29th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $7.22.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $6.22, for a total transaction of $54,425.00. Following the completion of the sale, the insider now directly owns 8,750 shares of the company’s stock, valued at approximately $54,425. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 5.50% of the company’s stock.
Tetraphase Pharmaceuticals Profile
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.